Efficacy and safety of albumin-bound paclitaxel in the treatment of advanced non-small cell lung cancer
- VernacularTitle:白蛋白结合型紫杉醇治疗晚期非小细胞肺癌的有效性和安全性
- Author:
Peng JI
1
;
Lijuan NING
1
;
Yongwu CHEN
1
;
Pengli ZHU
1
;
Fei WU
1
;
Yingqi WU
1
;
Hui YAN
1
;
Yadi GENG
1
;
Shengyu ZHANG
1
;
Aizong SHEN
1
Author Information
1. Dept. of Pharmacy，the First Affiliated Hospital of University of USTC，Division of Life Sciences and Medicine，Univerisity of Science and Technology of China/Anhui Technology Center for Clinical Comprehensive Evaluation of Drugs，Hefei 230001，China
- Publication Type:Journal Article
- Keywords:
albumin-bound paclitaxel;
paclitaxel;
non-small cell lung cancer;
efficacy;
safety
- From:
China Pharmacy
2022;33(22):2762-2765
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To observe the efficacy and safety of albumin-bound paclitaxel in the treatment of advanced non- small cell lung cancer （NSCLC）. METHODS Clinical data of patients with advanced NSCLC treated in our hospital from January 2018 to December 2021 were selected. According to their chemotherapy regimen，they were divided into albumin-bound paclitaxel group and paclitaxel group， with 100 patients in each group. Both groups received chemotherapy regimen containing Paclitaxel for injection （albumin-bound） or Paclitaxel injection for at least 2 cycles （every 21 days as a cycle）. The progression-free survival （PFS） and efficacy of the two groups were compared，and the occurrence of toxic and side effects were recorded. RESULTS The patients in albumin-bound paclitaxel group completed 430 cycles of chemotherapy， with an average of 4.3 cycles； patients in paclitaxel group completed 476 cycles of chemotherapy， with an average of 4.8 cycles. The median PFS （4.0 months） and the response rate （13.00%） of albumin-bound paclitaxel group were not significantly different from those of paclitaxel group （4.0 months，9.00%） （P＞0.05）. The disease control rate （99.00%） was significantly higher than that in paclitaxel group （89.00%）， and the incidences of leukopenia， neutropenia， thrombocytopenia，anemia， sensory neuropathy， fatigue，nausea and vomiting，joint myalgia in albumin-bound paclitaxel group were significantly lower than those in paclitaxel group （P＜0.05）. CONCLUSIONS Albumin-bound paclitaxel is effective in the treatment of advanced NSCLC， and it can better control the progression of the disease and is safer than ordinary paclitaxel.
